Avricore Health (AVCR) AI Stock Analysis

• Market Cap: C$7.39M
• Dividend Yield: N/A
• Average Volume (3M): 51.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: -59.28%
• EPS Growth: -1563.64%
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 101,289,665
• 10 Day Avg. Volume: 29,762
• 30 Day Avg. Volume: 51,367
• PEG Ratio: 1.92
• Price to Book (P/B): 2.80
• Price to Sales (P/S): 1.15
• P/FCF Ratio: 6.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.06 ▲(28.00% Upside)
• Action: Reiterated Date: 01/16/26
• Date: Action: Reiterated 01/16/26

The score is held down primarily by weak financial performance, led by a sharp TTM revenue decline, deep losses, and a return to free-cash-flow burn. Technicals provide some support with the stock trading above major moving averages and a positive MACD, but overbought signals (high RSI/Stoch) add risk. Valuation is constrained by a negative P/E and no dividend yield data.

Positive Factors

Pharmacy-based POC testing platform

Avricore's business model sells both services and platform capabilities to community pharmacies, creating multiple revenue levers (per-test, platform fees, program contracts). That diversified service+software model supports recurring program revenue and scalable site expansion if partnerships grow.

Multiple program revenue streams

The company's revenue mix (test delivery fees, platform/service revenue, and program contracts) creates varied monetization channels and reduces single-source dependency. Durable contractual program revenues and platform services can improve predictability and margin as scale increases.

Conservative leverage, low debt

Effectively zero debt lowers fixed interest costs and funding risk, giving management flexibility to support operations, invest in platform development, or pursue partnerships without immediate solvency pressure. This enhances resilience through cyclical revenue volatility.

Negative Factors

Sharp TTM revenue decline

A near-40% TTM revenue drop and deep negative margins materially reduce the company's ability to realize operating leverage from its decent gross margin. Sustained declines erode scale, compress cash generation, and make it harder to fund platform development or expand pharmacy programs.

Cash-flow volatility and recent FCF burn

The swing from positive FCF in 2024 to a TTM cash burn signals unstable cash generation. Persistent or recurring negative free cash flow would force external financing or cutbacks, constraining investments in sales execution and platform enhancements needed to regain growth.

Eroding equity and negative ROE

Falling shareholder equity and a very negative ROE reflect cumulative losses that can limit strategic flexibility. Continued erosion increases likelihood of dilutive capital raises, harms investor returns, and weakens the balance sheet's ability to absorb further operational setbacks.

Avricore Health Business Overview & Revenue Model

Company Description

Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a lab-accurate point of care testing platform for pharmacy. The company has strategic partnerships with Shoppers Drug Marts and Abbott. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.

How the Company Makes Money

Avricore Health generates revenue through the sale and deployment of its HealthTab platform in partnership with pharmacies and healthcare providers. The company earns money by charging fees for each test conducted on its platform and through subscription models that allow pharmacies to access and utilize the HealthTab technology. Additionally, Avricore Health benefits from strategic partnerships with leading diagnostic and pharmaceutical companies, which may provide funding or revenue-sharing opportunities to further expand its market presence. The company's revenue model is heavily reliant on the adoption of its technology by healthcare networks and the volume of diagnostic tests performed.

Avricore Health Financial Statement Overview

Summary

Overall fundamentals are pressured: TTM revenue fell sharply (-37.6%) and losses deepened (net margin ~-46%). The main offset is a low-debt balance sheet (debt-to-equity ~0.0) and a decent gross margin (~43%), but equity has eroded and cash flow turned back to modest TTM free-cash-flow burn.

Income Statement

TTM (Trailing-Twelve-Months) shows a sharp revenue decline (-37.6%) and a return to deep losses (net margin about -46%), despite a decent gross margin (~43%). Annual results show the business scaled meaningfully from 2021–2024, with improving gross margin versus earlier years, but profitability remains inconsistent (losses in most years and negative operating margins in the latest periods). Key strength is improved revenue base versus early history; key weakness is ongoing inability to convert that revenue into sustainable operating profit, especially with the latest TTM contraction.

Balance Sheet

The balance sheet is conservatively levered with effectively no debt in recent periods (debt-to-equity at 0.0 in 2024 and TTM), which reduces financial risk and interest burden. However, equity has fallen from 2023 to TTM (reflecting continued losses), and returns on equity remain strongly negative (TTM roughly -71%), signaling shareholder value dilution risk if losses persist. Overall, funding risk looks manageable due to low leverage, but profitability-driven erosion of equity is the main concern.

Cash Flow

Cash generation has been volatile: 2024 produced positive operating cash flow (~$1.0M) and positive free cash flow (~$0.8M), but TTM (Trailing-Twelve-Months) reverted to cash burn (operating cash flow about -$0.15M; free cash flow about -$0.26M) with a steep deterioration in free cash flow growth. A positive sign is that recent cash burn is smaller than net losses in TTM, but the swing from positive to negative cash flow raises execution and funding-risk questions if the downturn persists.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.92M	4.79M	3.49M	1.77M	122.81K	33.03K
Gross Profit	834.20K	1.88M	1.20M	456.79K	30.52K	17.48K
EBITDA	-590.41K	-208.44K	-275.14K	-629.76K	-1.64M	-930.40K
Net Income	-1.63M	-668.98K	-701.22K	-818.23K	-1.71M	-1.17M
Balance Sheet
Total Assets	1.33M	2.30M	2.54M	2.57M	2.28M	440.09K
Cash, Cash Equivalents and Short-Term Investments	541.75K	1.14M	286.57K	630.53K	2.01M	302.71K
Total Debt	0.00	0.00	40.00K	40.00K	40.00K	1.00M
Total Liabilities	35.88K	330.82K	529.22K	604.89K	84.48K	1.15M
Stockholders Equity	1.29M	1.97M	2.01M	1.96M	2.20M	-714.04K
Cash Flow
Free Cash Flow	-263.03K	799.27K	-386.46K	-1.64M	-1.37M	-1.22M
Operating Cash Flow	-146.71K	1.00M	660.40K	-437.83K	-1.23M	-1.22M
Investing Cash Flow	-119.03K	-205.35K	-1.05M	-1.21M	-140.36K	0.00
Financing Cash Flow	17.50K	56.60K	42.50K	253.88K	3.08M	1.51M

Avricore Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCR, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.06, indicating a bullish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 52.06 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:AVCR.

Avricore Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	48 Neutral	C$65.16M	-32.47	―	―	-21.89%	26.36%
AVCR	47 Neutral	C$7.39M	-4.67	-95.29%	―	-59.28%	-1563.64%
TELO	43 Neutral	C$4.82M	-2.38	-9999.00%	―	―	19.05%
NARA	42 Neutral	C$6.25M	-4.68	―	―	―	81.01%
GLAB	41 Neutral	C$3.06M	-22.65	―	―	―	9.06%

Avricore Health Corporate Events

Avricore to Expand HealthTab Testing Network Across North East London Pharmacies

Avricore Health is expanding its HealthTab point-of-care testing platform across North East London, rolling out to an additional 70 community pharmacy sites following the success of its NHS-linked cardiovascular programmes with Barts Health NHS Trust. The move underscores growing national recognition of community pharmacies in cardiovascular care, aligns with NHS efforts to shift services from hospitals into the community, and demonstrates HealthTab’s scalability within complex NHS environments. By offering a turnkey, cloud-based infrastructure that integrates analyzers, patient results and quality-control data, and by partnering with reference lab CEQAL for rigorous quality management, Avricore is positioning HealthTab as a high-standard, scalable solution for preventive and treatment-linked care pathways across England.

The most recent analyst rating on (TSE:AVCR) stock is a Hold with a C$0.05 price target. To see the full list of analyst forecasts on Avricore Health stock, see the TSE:AVCR Stock Forecast page.

Avricore Health’s HealthTab Expands Role in NHS Cardiovascular Care Pilot

Avricore Health’s HealthTab platform is being utilized in a new pilot program by Barts Health NHS Trust to deliver cholesterol-lowering injections through community pharmacies in the UK. This initiative marks a significant expansion of HealthTab’s role from primary to secondary prevention, integrating with the Ortus-iHealth platform to connect pharmacy-generated results directly into hospital systems. Supported by a British Heart Foundation grant, the pilot aims to decentralize cardiovascular therapy, reduce hospital burdens, and enhance long-term lipid management, aligning with NHS policies to increase the role of community pharmacies in chronic condition management.